RXO enters the back half of May with short sellers on the defensive — earnings delivered a sharp rally, analysts lifted targets across the board, and the put/call ratio suddenly spiked to its most defensive reading in months, all in the same five-day stretch.
The short position has been quietly unwinding for weeks, and this week accelerated that move. Short interest as a percentage of free float has fallen from a peak of roughly 12.1% in early April to 10.1% now — a sustained retreat that tracks closely with the stock's 13% one-month gain to $21.13. Short sellers added to the position aggressively during the tariff-shock selloff in early April, then started covering as the stock stabilised. The cost to borrow remains negligible at 0.44%, and borrow availability is running at 304% — roughly three shares available to lend for every one currently shorted. That is a comfortable lending environment with no squeeze pressure. The ORTEX short score has also eased from 65.5 a fortnight ago to 61.2, reflecting both the covering activity and the looser borrow conditions.
Options, however, are sending a different signal. The put/call ratio jumped to 5.72 on Tuesday — more than twice its 20-day average of 2.32, and a full 2.3 standard deviations above it. That is an unusually sharp single-day spike. It follows the stock's 10.6% one-day gain on May 19, suggesting some holders are buying downside protection after a move that fast. The 52-week high on the PCR is 16.5, so the reading is elevated but not at crisis levels; still, the jump from 1.6 the prior session to 5.7 is a notable one-day shift in hedging demand.
The Street has turned more constructive, though with caveats. Following Q1 results on May 7, nearly every covering analyst raised their price target — UBS moved from $17 to $22, Citi from $17 to $24, Truist from $20 to $26, Wells Fargo from $15 to $22, and Barclays from $17 to $20. The exception was Morgan Stanley, which raised its target but simultaneously downgraded from Overweight to Equal-Weight. Stifel then upgraded outright to Buy with a $22 target on May 15. The consensus sits at Hold with four buys and twelve holds — bulls point to Coyote integration gains and a 24% year-over-year increase in Final Mile stops; bears flag an 8% decline in truckload volumes and weak automotive demand that has forced EPS revisions lower. With the stock at $21.13 and the majority of post-earnings targets clustered between $20 and $26, the implied upside is modest. The EV/EBITDA multiple has expanded by roughly 2 turns over the past week to 25.8x — a stretch for a freight broker with near-term volume headwinds.
Institutional ownership is concentrated. Orbis Investment Management holds 22% of shares, and MFN Partners holds a further 17%. Both added modestly in the most recent quarter. Hood River Capital Management and Frontier Capital Management both made material additions — Hood River built a new position of 2.5 million shares and Frontier added over 1 million. That degree of concentration is a structural feature worth tracking: a change in conviction from Orbis or MFN would move the stock meaningfully. On the insider side, CEO Drew Wilkerson received a stock award in May and sold 40,370 shares at $19.59 — a routine equity-plan liquidation rather than a directional signal. Earlier March sales at $13.23 by the CEO and CFO likewise appear routine against the backdrop of stock awards received on the same date.
Close peer CVLG gained 12.7% on the week, topping the peer group, while ARCB added 5.1% and LSTR 3.6%. RXO's 5.4% weekly gain keeps it in the middle of the transport pack — the standout move was Tuesday's single-day surge, not the weekly tape. The EPS momentum factor scores are exceptional — 100th percentile over 30 days and 99th over 90 days — while the analyst recommendation differential also ranks at the top of the universe. What to watch next is whether the post-earnings short covering continues at the current pace, or whether the options hedging spike on Tuesday signals that the fast money is starting to fade the bounce.
See the live data behind this article on ORTEX.
Open RXO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
